RESEARCH ARTICLE

EVALUATION OF COAGULATION PROFILE IN PATIENTS WITH PREGNANCY INDUCED HYPERTENSION IN PATIENTS ATTENDING A TERTIARY CARE HOSPITAL IN NORTH INDIA.

Farhat Ali Lone¹, Sabha Malik¹, Shaheera Ajaz¹, Liaqat Ahmad Malik² And Parvaiz Mohiudin Dar².
1. Department of Obstetrics and Gynaecology, Sher-e-Kashmir Institute of Medical Sciences (SKIMS), Soura J&K.
2. Department of General and minimal access Surgery, Sher-e-Kashmir Institute of Medical Sciences(SKIMS), Soura J&K.

Abstract

Pregnancy induced hypertension (PIH) is one of the most common causes of both maternal and neonatal morbidity and associated with adverse pregnancy outcomes. Profound changes in coagulation and fibrinolytic system occur during normal pregnancy causing hypercoagulable state. Early identification of high risk women and monitoring derangements in their coagulation system are surely pivotal in the prevention of complications. Hence, this study was undertaken to compare the coagulation profile in pre-eclamptic and eclamptic patients with normotensive pregnant patients. Hypertension is one of the common medical complications of pregnancy and contributes significantly to maternal and perinatal morbidity and mortality. Hypertension is a sign of an underlying pathology which may be pre-existing or appear for the first time during pregnancy. Various haematological changes like numerical and functional platelet abnormalities, alteration in haemoglobin and erythrocyte parameters and hypercoagulable state may be seen.

Aims and Objectives: Evaluation of coagulation profile in PIH.

Materials and Methods: A one year study was carried in the department of gynaecology and obstetrics on 100 PIH cases. Coagulation profile (PT, aPTT, INR and D-dimer) was done in all cases and values were correlated with the severity of PIH.

Results: Total of 100 cases were included in the study. 32 were mild GH, 17cases were severe GH, 35 cases were mild pre-eclampsia and 16cases were in severe pre-eclampsia group. Prolonged PT, aPTT and D-Dimer was seen in 15 cases, 42 cases and 38 cases respectively. In our study we observed increased mean aPTT of 31.61±2.89 and increased D-Dimer of 0.34±0.31 in severe pre-eclampsia patients. Hence we emphasize that raised aPTT, D-Dimer are alarming signs for aggressive treatment.

Conclusion: Raised aPTT and D-dimer are fairly good indicator of severe pre-eclampsia and needs aggressive treatment.
Introduction:
Hypertensive disorders complicates 5 to 10 % of all pregnancies, contribute significant to perinatal and maternal mortality and morbidity. According to systematic review by WHO hypertensive disorders account for 16% of maternal deaths in developed countries1. Hypertensive disorders in pregnancy is one of the commonest medical disorders in pregnancy diagnosed by obstetricians in clinical practice and is one of the major causes of maternal & perinatal morbidity and mortality2. Approximately 1,00,000 women die worldwide per annum because of eclampsia2. It is said that preeclampsia and eclampsia contribute to death of a woman every 3 minute worldwide3 Preeclampsia is a common dangerous condition for both mother and baby and is also predictable in onset and progression.

Hypertension is one of the most common medical complications of pregnancy. It contributes significantly to maternal and perinatal morbidity and mortality. Hypertension is a sign of an underlying pathology which may be pre-existing or appear for the first time during pregnancy4. Hypertension affects 7-15% of all pregnancies. It is associated with 16% of all maternal mortality and 20% of all perinatal mortality in India4,5.

Pregnancy induced hypertension (PIH) is defined as hypertension that develops as the direct result of the gravid state. It includes, i) Gestational hypertension, ii) Preeclampsia, iii) Eclampsia.

Hematological abnormalities such as thrombocytopenia and decrease in some plasma clotting factors may develop in preeclamptic women6.

In pregnancies with preeclampsia coagulation cascade is generally activated. Preeclampsia is a highly thrombotic and pro-coagulant state with platelet activation and thrombin and fibrin formation. About 20% of patients have altered coagulation7. Profound changes in coagulation and fibrinolytic system occur during normal pregnancy causing hypercoagulable state. The prothrombotic state may culminate in a process of chronic disseminated intravascular coagulation (DIC) leading to changes in kidney and placenta8. These underlying coagulation abnormalities increase the risk of bleeding complications especially during operative deliveries. These subtle changes consistent with DIC occurring in pre-eclampsia and are potentially serious9. In the mother, pre-eclampsia may cause premature cardiovascular diseases, such as chronic hypertension, heart disease and stroke. Later in life, while children born after pre-eclamptic pregnancies and who are relatively small at birth, have an increased risk of stroke, coronary heart disease and metabolic syndrome in adult life10. Thus, early identification of such high risk women and monitoring derangements in their coagulation system are surely pivotal in the prevention of complications. Hence, this study was undertaken to compare the coagulation profile in pre-eclamptic and eclamptic patients with normotensive pregnant patients.

Aims And Objectives:
Evaluation of coagulation profile in PIH patients.

Materials And Methods:
The study was carried out in the department of gynaecology and obstetrics SKIMS srinagar. One hundred cases diagnosed as PIH with Blood Pressure of ≥ 140/90 mm of Hg detected after 20th weeks of gestation were included in the study. Clinical details were collected from all cases. The cases with pre-existing hypertension and associated co-morbid diseases such as diabetes mellitus, auto immune disorders, ITP, neoplastic diseases, heart diseases and cases on anti-coagulants were excluded from the study. After obtaining consent, under aseptic precaution, venous blood was collected in sodium citrate vacutainer tube. Sample was tested for coagulation profile i.e. PT, aPTT, D-Dimer in fully automated coagulation analyser (CA-1500). PIH cases were classified in to following categories: A. Gestational hypertension.1) Mild gestational hypertension, 2) Severe gestational hypertension.

B. Pre-eclampsia. 1) Mild pre-eclampsia, 2) Severe pre-eclampsia.

Statistical Methods:
The recorded data was compiled and entered in a spreadsheet (Microsoft Excel) and then exported to data editor of SPSS Version 20.0 (SPSS Inc., Chicago, Illinois, USA). Continuous variables were expressed as Mean±SD and categorical variables were summarized as frequencies and percentages. Graphically the data was presented by bar diagrams. Analysis of variance (ANOVA) was employed to compare coagulation profile in different categories of PIH. A P-value of less than 0.05 was considered statistically significant.
Results:-
One hundred cases diagnosed as PIH were analysed for coagulation profile. Of 100 cases majority i.e. 36% of the patients were of the age group 25-30 years. (Table. 1) The age of the youngest patient was 20 years and that of oldest was 40 years. 25to 30 years is the commonest age group for gestational hypertension (GH), both mild (15cases) and severe (7cases). An equal number of severe GH was also seen in the 26 to 30 age group. Mild and severe pre-eclampsia was more frequent in the 26 to 30 age group, (16 and 8 cases respectively). This probably indicates that severity of complications increases with the age of the patient. (Table. 2) of the hundred PIH cases.

Table 1: Demographic characteristics

| Age (years) | Frequency | Percentage |
|------------|-----------|------------|
| 20-25      | 17        | 17%        |
| 25-30      | 36        | 36%        |
| 30-35      | 31        | 31%        |
| 35-40      | 16        | 16%        |
| Total      | 100       | 100%       |

Total number of patients in this study were 100 with maximum number of patients in age group of 25 to 30 years followed by patients in age group of 30 to 35 years. This result showed that PIH increases with increasing age among women(67% in age 25 and above).

Table 2:- Table showing age wise distribution of various categories of PIH cases

| Age (years) | Mild GH | Severe GH | Mild Preeclampsia | Severe PREEclampsia |
|-------------|---------|-----------|-------------------|---------------------|
| No.         | %age    | No.       | %age              | No.                 | %age              |
| 20-25       | 3       | 9.4       | 3                 | 17.6                | 7                 | 20.0              | 2                 | 12.5               |
| 25-30       | 15      | 46.9      | 6                 | 35.3                | 16                 | 45.7              | 8                 | 50.0               |
| 30-35       | 11      | 34.4      | 7                 | 41.2                | 10                 | 28.6              | 4                 | 25.0               |
| 35-40       | 3       | 9.4       | 1                 | 5.9                 | 2                  | 5.7               | 2                 | 12.5               |
| Total       | 32      | 100       | 17                | 100                 | 35                 | 100               | 16                | 100                |

This table is showing that among 100 patients mild gestational hypertension (46.9%) was in age group of 25 to 30 years; severe gestational hypertension (34.4%) in 30 to 35 years age group; mild pre-eclampsia (45.7%) in 25 to 30 years age group and severe pre-eclampsia (50%) in age group in 25 to 30 years.

Table 3:-Table showing d D dimers in various categories of PIH cases

| D Dimer | Mild GH | Severe GH | Mild Preeclampsia | Severe Eclampsia |
|---------|---------|-----------|-------------------|-----------------|
| No.     | %age    | No.       | %age              | No.             | %age              |
| <0.3    | 19      | 59.4      | 8                 | 47.1            | 25                | 71.4              | 10                | 62.5               |
| 0.3-1   | 13      | 40.6      | 9                 | 52.9            | 10                | 28.6              | 6                 | 37.5               |
| Total   | 32      | 100       | 17                | 100             | 35                | 100               | 16                | 100                |

Table 4:-Comparison of coagulation profile in different categories of PIH

| Variable           | Mild GH | Severe GH | Mild Preeclampsia | Severe Preeclampsia | P-value |
|--------------------|---------|-----------|-------------------|---------------------|---------|
| Age (years)        | 25.8±2.41 | 26.3±3.19 | 25.4±2.87 | 25.7±3.24 | 0.997 |
| Gestational age (weeks) | 36.2±3.65 | 35.3±3.19 | 36.7±2.72 | 35.5±3.41 | 0.991 |
| PT                 | 12.43±1.93 | 13.41±1.32 | 13.09±2.05 | 12.97±1.97 | 0.989 |
| APTT               | 25.92±3.07 | 26.67±2.71 | 28.82±3.23 | 31.61±2.89 | 0.685 |
| D Dimer            | 0.29±0.46 | 0.32±0.27 | 0.26±0.29 | 0.34±0.31 | 0.876 |

This table shows value of aPTT increases with severity of PIH with maximum value in severe preeclampsia (31.61±2.89); also D dimers were in in higher range in severe preeclampsia as compared to others. So APTT and D-dimer can predict the severity of PIH and helps us to plan and manage patient accordingly to decrease maternal and fetal morbidity and mortality.
Discussion:
Preeclampsia is an idiopathic multisystem disorder specific to human pregnancy and the puerperium. Hematological abnormalities such as thrombocytopenia and decrease in some plasma clotting factors may develop in preeclamptic women. Subtle changes suggesting disseminated intravascular coagulation (DIC) is one of the serious outcome of preeclampsia. Thus, coagulation testing is to be done in these patients to rule out DIC and HELLP (hemolysis, enzyme elevation and low platelet) syndrome. From the historical point of view, earlier it was stated that only serial measurements of platelet count was adequate for intrapartum screening. Later, combination of platelet count and aPTT, platelet count and liver function tests, platelet count and lactatedehydrogenase, platelet count and antithrombin were suggested for early detection and screening of the patients with preeclampsia. It was observed that abnormal PT, aPTT and fibrinogen levels with platelet counts of less than 100,000/mm3 were seen in preeclampsia. So the physician can safely follow the platelet counts of the patients with severe preeclampsia. In our study a total of 100 PIH cases referred to the department of pathology from ANC clinic were evaluated for coagulation profile. Majority of the cases were in the age group of 26-30 years with mean of 28±3.02, which is comparable to Onisai et al study where they observed that the mean age of PIH was 29.8 years. In the present study PT was prolonged in 5% which is in concordance with the study conducted by FitzGerald et al. aPTT was prolonged in 20% of PIH cases in our study as compared with other studies such as FitzGerald et al. wherein 25% of cases had a prolonged aPTT. However Onisai et al observed no change in PT and aPTT in their study. In the present study D-Dimer levels increased in 38% of PIH cases which is in concordance with the study conducted by Takao et al.

Prolonged PT, aPTT and D-Dimer was seen in 5 cases, 20 cases and 38 cases respectively in our study and increased mean aPTT of 31.61±2.89 and increased D-Dimer of 0.34±0.31 in severe preeclampsia patients was noted. Hence we emphasize that raised aPTT, D-Dimer are alarming signs for aggressive treatment.

Conclusion:
The coagulation parameters, especially aPTT and D-dimer can be used to monitor the progression of gestational hypertension to preeclampsia. Raised aPTT and D-dimer are fairly good indicators of severe preeclampsia and needs aggressive treatment.

Acknowledgements:
The authors acknowledges the support provided by the co authors and patients.

Conflict of interest
It is certified that there was not any conflict of interest.

Competing Interests
The authors declare that there were no competing interests.
References:
1. Khan KS, Wojdyla D, et al. WHO analysis of causes of maternal death: a systematic review. Lancet. 2006;367:1066.
2. Shah MR. Hypertensive disorders in pregnancy. 1st edn published by Jaypee. 2007: 1-10. 3. Cunningham FG, Leveno KJ, Bloom SL, Hauth JC, Gilstrap III, LC, Wenstrom KD. Hypertensive disorders in pregnancy. Ch 37 In William Obstetrics. 21st edn published by McGraw Hill Company; 2002: 871-90.
3. Cunningham FG, Kennedy J, Leveno, Steven L. Bloom, John C. Pregnancy induced hypertension. In: Kenneth J. Leveno, Steven L. Bloom editor. William Obstetrics. 23rd ed. New York: McGraw-Hill; 2010. p. 706-56.
4. Dutta DC. Pregnancy induced hypertension. In: Dutta DC editor. Textbook of Obstetrics including Perinatology and Contaception, 7th ed. Kolkata: New Central Book Agency (P) Ltd; 2011. p. 219-40.
5. Norwitz ER, Hsu CD, Repke JT. Acute complications of preeclampsia. Clin Obstet Gynecol 2002; 45:29.
6. Onisai M, Vladareaner AM, Bumbea H, Clorascu M, Pop C, Andrei C, et al. A study of haematological picture and of platelet function in preeclampsia-report of a series of cases. J of Clin Med 2009; 4:326-7.
7. Weiner CP, Brandt J. Plasma antithrombin-III activity: An aid in the diagnosis of pre-eclampsia-eclampsia. Am J Obstet Gynecol 1982; 142:275-81.
8. Jahromi BN, Rafiee SH. Coagulation factors in severe preeclampsia. IRCMJ 2009; 11(3):321-4.
9. FitzGerald MP, Floro C, Siegel J, Hernandez E. Laboratory findings in hypertensive disorders of pregnancy. J Nat Med Assoc 1996; 88(12):794-98.
10. Usmond C, Kajantie E, Forsén TJ, Eriksson JG, Barker DJ. Infant growth and stroke in adult life: The Helsinki Birth Cohort Study. Stroke 2007; 38(2):264-70.
11. Norwitz ER, Hsu CD, Repke JT. Acute complications of preeclampsia. Clin Obstet Gynecol 2002; 45:29.
12. Metz J, Cincotta R, Francis M, DeRosa L, Balloch A. Screening for consumptive coagulopathy in preeclampsia. Int J Gynecol Obstet 1994; 46:3-9.
13. Barron WM, Heckerling P, Hibbard JU, Fisher S. Reducing unnecessary coagulation testing in hypertensive disorders of pregnancy. Obstet Gynecol 1999; 94:364-70.
14. Leduc L, Wheeler JM, Kirshon B, Mitchell P, Cotton DB. Coagulation profile in severe preeclampsia. Obstet Gynecol 1992; 79:14-8.
15. Kramer RL, Izquierdo LA, Gilson GI, Curet LB, Qualls R. "Preeclamptic labs" for evaluating hypertension in pregnancy. J Reprod Med 1997; 42:223-8.
16. Osmanagaoglu MA, Topcuoglu K, Ozeren M, Bozkaya H. Coagulation inhibitors in preeclamptic pregnant women. Arch Gynecol Obstet 2005; 271:227-30.
17. Fitzgerald MP, Floro C, Siegel J, Hernandez E. Laboratory Findings in hypertensive disorders of pregnancy. J Natl Med Assoc 1996; 88:794-98.
18. Kobayashi T, Tokunaga N, Sugimura M, Kanayama N, Terao T. Predictive Values of Coagulation/Fibrinolysis Parameters for the Termination of Pregnancy Complicated by severe preeclampsia. Semin Thromb Hemost 2001; 27:137-41.